These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 29502411)

  • 1. Evaluation of an Anti-HER2 Nanobody Labeled with
    Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
    Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer.
    Rodak M; Dekempeneer Y; Wojewódzka M; Caveliers V; Covens P; Miller BW; Sevenois MB; Bruchertseifer F; Morgenstern A; Lahoutte T; D'Huyvetter M; Pruszyński M
    Mol Cancer Ther; 2022 Dec; 21(12):1835-1845. PubMed ID: 36129807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
    Dekempeneer Y; Bäck T; Aneheim E; Jensen H; Puttemans J; Xavier C; Keyaerts M; Palm S; Albertsson P; Lahoutte T; Caveliers V; Lindegren S; D'Huyvetter M
    Mol Pharm; 2019 Aug; 16(8):3524-3533. PubMed ID: 31268724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.
    Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Lyerly HK; Zalutsky MR
    J Nucl Med; 2014 Apr; 55(4):650-6. PubMed ID: 24578241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha radioimmunotherapy using
    Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
    Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
    Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
    J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.
    Zhou Z; Vaidyanathan G; McDougald D; Kang CM; Balyasnikova I; Devoogdt N; Ta AN; McNaughton BR; Zalutsky MR
    Mol Imaging Biol; 2017 Dec; 19(6):867-877. PubMed ID: 28409338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.
    Zhou Z; Chitneni SK; Devoogdt N; Zalutsky MR; Vaidyanathan G
    Bioorg Med Chem; 2018 May; 26(8):1939-1949. PubMed ID: 29534937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
    D'Huyvetter M; Vincke C; Xavier C; Aerts A; Impens N; Baatout S; De Raeve H; Muyldermans S; Caveliers V; Devoogdt N; Lahoutte T
    Theranostics; 2014; 4(7):708-20. PubMed ID: 24883121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with
    Yook S; Cai Z; Jeong JJ; Lu Y; Winnik MA; Pignol JP; Reilly RM
    Mol Pharm; 2020 Apr; 17(4):1226-1236. PubMed ID: 32022567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
    Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G
    Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of [
    Ducharme M; Hall L; Eckenroad W; Cingoranelli SJ; Houson HA; Jaskowski L; Hunter C; Larimer BM; Lapi SE
    Mol Pharm; 2023 Sep; 20(9):4629-4639. PubMed ID: 37552575
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Zhao L; Gong J; Qi Q; Liu C; Su H; Xing Y; Zhao J
    Int J Nanomedicine; 2023; 18():1915-1925. PubMed ID: 37064291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators.
    D'Huyvetter M; Aerts A; Xavier C; Vaneycken I; Devoogdt N; Gijs M; Impens N; Baatout S; Ponsard B; Muyldermans S; Caveliers V; Lahoutte T
    Contrast Media Mol Imaging; 2012; 7(2):254-64. PubMed ID: 22434639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.
    Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Zalutsky MR
    Nucl Med Biol; 2013 Jan; 40(1):52-9. PubMed ID: 23159171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Efficacy of
    Dekempeneer Y; Caveliers V; Ooms M; Maertens D; Gysemans M; Lahoutte T; Xavier C; Lecocq Q; Maes K; Covens P; Miller BW; Bruchertseifer F; Morgenstern A; Cardinaels T; D'Huyvetter M
    Mol Pharm; 2020 Sep; 17(9):3553-3566. PubMed ID: 32787284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.
    Deken MM; Kijanka MM; Beltrán Hernández I; Slooter MD; de Bruijn HS; van Diest PJ; van Bergen En Henegouwen PMP; Lowik CWGM; Robinson DJ; Vahrmeijer AL; Oliveira S
    J Control Release; 2020 Jul; 323():269-281. PubMed ID: 32330574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
    Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
    Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
    [No Abstract]   [Full Text] [Related]  

  • 20. (18)F-nanobody for PET imaging of HER2 overexpressing tumors.
    Xavier C; Blykers A; Vaneycken I; D'Huyvetter M; Heemskerk J; Lahoutte T; Devoogdt N; Caveliers V
    Nucl Med Biol; 2016 Apr; 43(4):247-52. PubMed ID: 27067045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.